- Conditions
- Type 1 Diabetes
- Interventions
- Insulin, Insulin LISPRO
- Drug
- Lead sponsor
- Hompesch, Marcus, M.D.
- Individual
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Chula Vista, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1465–1488
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
- Interventions
- OriCAR-017
- Drug
- Lead sponsor
- OriCell Therapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Lymphoma
- Interventions
- Glofitamab, Tocilizumab, Obinutuzumab, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Orlando, Florida • Chicago, Illinois + 5 more
- Conditions
- Metastatic Melanoma and Other Solid Tumors
- Interventions
- BAY2666605
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee • Houston, Texas • San Antonio, Texas
- Conditions
- Bronchial Asthma
- Interventions
- 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product, Placebo
- Drug
- Lead sponsor
- Cipla Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
- Interventions
- Cinacalcet
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 28 Days to 2190 Days
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more
- Conditions
- Dilated Cardiomyopathy (DCM), BAG3 Mutation Associated Dilated Cardiomyopathy
- Interventions
- AFTX-201
- Genetic
- Lead sponsor
- Affinia Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Miami, Florida • Kansas City, Missouri • New York, New York + 1 more
- Conditions
- Hepatitis B, HBV
- Interventions
- Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
- Conditions
- Pneumonia, Bacterial, Community-acquired
- Interventions
- Ceftaroline, Levofloxacin
- Drug
- Lead sponsor
- Gary E. Stein, Pharm.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Lansing, Michigan
- Conditions
- HIV Infections
- Interventions
- darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Asthma
- Interventions
- Albuterol Spiromax®, ProAir® HFA
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Costa Mesa, California
- Conditions
- DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Disorders, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, Neurodegenerative Diseases
- Interventions
- Placebo, AOC 1001
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
- Conditions
- Heart Failure, Congestive
- Interventions
- CD-NP
- Drug
- Lead sponsor
- Nile Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- LGMD2I
- Interventions
- PF 06252616
- Drug
- Lead sponsor
- Kathryn Wagner
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Primary Open-angle Glaucoma (POAG), Ocular Hypertension
- Interventions
- SHP639 (n=60), Placebo Comparator (n=24)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Opiate Addiction
- Interventions
- 6β-Naltrexol escalating doses from 0.05-0.5 mg IV
- Drug
- Lead sponsor
- California Pacific Medical Center Research Institute
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hepatitis Autoimmune Disease, Hepatitis
- Interventions
- LY3981314
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Dallas, Texas
- Conditions
- Pulmonary Hypertension
- Interventions
- VentaProst
- Combination Product
- Lead sponsor
- Aerogen Pharma Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- TERN-501, TERN-101, Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more
- Conditions
- Healthy
- Interventions
- clopidogrel, placebo, omeprazole
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Seasonal Influenza Preventative Vaccine Pharmacodynamics
- Interventions
- VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large)
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Parkinson's Disease
- Interventions
- AVE8112, Placebo
- Drug
- Lead sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Insulin LISPRO, recombinant human insulin
- Drug
- Lead sponsor
- Biodel
- Industry
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-06291874, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Anaheim, California • Chula Vista, California • South Miami, Florida